ESMO Gastrointestinal Cancers Congress 2026
Trials whose public commentary places their results at ESMO Gastrointestinal Cancers Congress 2026, Jul 1–4, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
7 trials: 1 with a report and 6 with no report yet. Organised by European Society for Medical Oncology (ESMO); Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Other · 1 | |||||||
| RMC-9805-001 RMC-9805; RMC-9805 plus daraxonrasib (RMC-6236) placed at ESMO Gastrointestinal Cancers Congress 2026 by 2 sources NCT06040541 · Revolution Medicines, Inc. | advanced KRAS G12D-mutant solid tumors | Phase 1 | 117 | 45 | Focused | Nov 2, 2026 | Preview |
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Colorectal cancer · 1 | |||||||
| KRYSTAL-10 adagrasib (MRTX849) plus cetuximab placed at ESMO Gastrointestinal Cancers Congress 2026 by 6 sources NCT04793958 · Mirati Therapeutics Inc. DeepView → | advanced colorectal cancer with KRAS G12C mutation | Phase 3 | Deep | View | |||
| Gastroesophageal adenocarcinoma · 1 | |||||||
| HERIZON-GEA-01 zanidatamab; zanidatamab plus tislelizumab placed at ESMO Gastrointestinal Cancers Congress 2026 by 2 sources NCT05152147 · Jazz Pharmaceuticals DeepView → | HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma | Phase 3 | Deep | View | |||
| Hepatocellular carcinoma · 2 | |||||||
| EMERALD-1 durvalumab plus bevacizumab; durvalumab placed at ESMO Gastrointestinal Cancers Congress 2026 by 5 sources NCT03778957 · AstraZeneca DeepView → | locoregional hepatocellular carcinoma | Phase 3 | Deep | View | |||
| EMERALD-3 durvalumab plus tremelimumab plus lenvatinib; durvalumab plus tremelimumab placed at ESMO Gastrointestinal Cancers Congress 2026 by 4 sources NCT05301842 · AstraZeneca DeepView → | locoregional hepatocellular carcinoma | Phase 3 | Deep | View | |||
| Other · 2 | |||||||
| GLEAM zolbetuximab placed at ESMO Gastrointestinal Cancers Congress 2026 by 7 sources NCT03816163 · Astellas Pharma Global Development, Inc. DeepView → | first-line CLDN18.2-positive metastatic pancreatic adenocarcinoma | Phase 2 | Deep | View | |||
| STAR-221 domvanalimab plus zimberelimab placed at ESMO Gastrointestinal Cancers Congress 2026 by 2 sources NCT05568095 · Arcus Biosciences, Inc. DeepView → | previously untreated advanced upper gastrointestinal tract adenocarcinoma | Phase 3 | Deep | View | |||